Lake Street Capital Begins Coverage on InspireMD (NYSE:NSPR)

Investment analysts at Lake Street Capital assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $5.00 price target on the stock. Lake Street Capital’s price target indicates a potential upside of 58.73% from the company’s previous close.

Several other research firms also recently commented on NSPR. Piper Sandler reiterated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a report on Tuesday, September 17th. StockNews.com initiated coverage on InspireMD in a report on Wednesday, December 4th. They issued a “sell” rating on the stock.

InspireMD Price Performance

Shares of NSPR traded up $0.01 during midday trading on Wednesday, hitting $3.15. 25,077 shares of the company traded hands, compared to its average volume of 29,285. The stock has a 50-day moving average of $2.64 and a 200-day moving average of $2.67. InspireMD has a one year low of $1.81 and a one year high of $3.42. The firm has a market cap of $82.16 million, a P/E ratio of -4.20 and a beta of 0.98.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The firm had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. Sell-side analysts forecast that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.